Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,252

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

Open access
O'Connor, C.M., Starling, R.C., Hernandez, A.F., Armstrong, P.W., Dickstein, K., Hasselblad, V., Heizer, G.M., Komajda, M., Massie, B.M., McMurray, J.J.V., Nieminen, M.S., Reist, C.J., Rouleau, J.L., Swedberg, K., Adams, K.F., Anker, S.D., Atar, D., Battler, A., Botero, R., Bohidar, N.R., Butler, J., Clausell, N., Corbalán, R., Costanzo, M.R., Dahlstrom, U., Deckelbaum, L.I., Diaz, R., Dunlap, M.E., Ezekowitz, J.A., Feldman, D., Felker, G.M., Fonarow, G.C., Gennevois, D., Gottlieb, S.S., Hill, J.A., Hollander, J.E., Howlett, J.G., Hudson, M.P., Kociol, R.D., Krum, H., Laucevicius, A., Levy, W.C., Méndez, G.F., Metra, M., Mittal, S., Oh, B.-H., Pereira, N.L., Ponikowski, P., Tang, W.H.W., Tanomsup, S., Teerlink, J.R., Triposkiadis, F., Troughton, R.W., Voors, A.A., Whellan, D.J., Zannad, F., Califf, R.M.·2011·New England Journal of Medicine

Abstract

BACKGROUND: Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent. METHODS: We randomly assigned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. Coprimary end points were the change in dyspnea at 6 and 24 hours, as measured on a 7-point Likert scale, and the composite end point of rehospitalization for heart failure or death within 30 days. RESULTS: Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P=0.03) and 24 hours (68.2% vs. 66.1%, P=0.007), but the prespecified level for significance (P≤0.005 for both assessments or P≤0.0025 for either) was not met. The rate of rehospitalization for heart failure or death from any cause within 30 days was 9.4% in the nesiritide group versus 10.1% in the placebo group (absolute difference, -0.7 percentage points; 95% confidence interval [CI], -2.1 to 0.7; P=0.31). There were no significant differences in rates of death from any cause at 30 days (3.6% with nesiritide vs. 4.0% with placebo; absolute difference, -0.4 percentage points; 95% CI, -1.3 to 0.5) or rates of worsening renal function, defined by more than a 25% decrease in the estimated glomerular filtration rate (31.4% vs. 29.5%; odds ratio, 1.09; 95% CI, 0.98 to 1.21; P=0.11). CONCLUSIONS: Nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect on dyspnea when used in combination with other therapies. It was not associated with a worsening of renal function, but it was associated with an increase in rates of hypotension. On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure. (Funded by Scios; ClinicalTrials.gov number, NCT00475852.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1100171

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 1,252

Metadata

Authors
O'Connor, C. M., Starling, R. C., Hernandez, A. F., Armstrong, P. W., Dickstein, K., Hasselblad, V., Heizer, G. M., Komajda, M., Massie, B. M., McMurray, J. J. V., Nieminen, M. S., Reist, C. J., Rouleau, J. L., Swedberg, K., Adams, K. F., Anker, S. D., Atar, D., Battler, A., Botero, R., Bohidar, N. R., Butler, J., Clausell, N., Corbalán, R., Costanzo, M. R., Dahlstrom, U., Deckelbaum, L. I., Diaz, R., Dunlap, M. E., Ezekowitz, J. A., Feldman, D., Felker, G. M., Fonarow, G. C., Gennevois, D., Gottlieb, S. S., Hill, J. A., Hollander, J. E., Howlett, J. G., Hudson, M. P., Kociol, R. D., Krum, H., Laucevicius, A., Levy, W. C., Méndez, G. F., Metra, M., Mittal, S., Oh, B.-H., Pereira, N. L., Ponikowski, P., Tang, W. H. W., Tanomsup, S., Teerlink, J. R., Triposkiadis, F., Troughton, R. W., Voors, A. A., Whellan, D. J., Zannad, F., & Califf, R. M.
Venue
New England Journal of Medicine
Published
2011-07-07
Volume
365
Issue
1
Pages
32-43
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2069722675
Cited by
1,252
References
2
FWCI
77.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. https://app.cochat.ai/papers/10.1056/nejmoa1100171
The paper
O'Connor, C. M., Starling, R. C., Hernandez, A. F., Armstrong, P. W., Dickstein, K., Hasselblad, V., Heizer, G. M., Komajda, M., Massie, B. M., McMurray, J. J. V., Nieminen, M. S., Reist, C. J., Rouleau, J. L., Swedberg, K., Adams, K. F., Anker, S. D., Atar, D., Battler, A., Botero, R., . . . Califf, R. M. (2011). Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1100171

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.